LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.
CIN: L24230GJ1995PLC024288, **Ph. No.:** +91-79-4107-8000,
Website: www.lincolnpharma.com, **E-Mail:** investor@lincolnpharma.com

Statement of Standalone Un-Audited Financial Results for the Quarter Ended on 30-June-2026.

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30/06/2026 (Un-Audited)	31/03/2026 Refer No. 3	30/06/2025 (Un-Audited)	31/03/2026 (Audited)
1	**Income**				
	A) Revenue From Operations	17,728.21	18,727.73	15,406.67	67,102.99
	B) Other Income	2,426.46	(419.53)	1,527.17	3,345.40
	Total Income (1)	**20,154.67**	**18,308.20**	**16,933.84**	**70,448.39**
2	**Expenses**				
	A) Cost of Material Consumed	5,857.86	7,372.58	6,096.93	23,957.41
	B) Purchase of Stock-In-Trade	2,093.36	1,644.69	1,583.06	7,902.55
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	563.09	(110.23)	(741.56)	(743.96)
	D) Employee Benefits Expenses	3,331.03	3,245.79	3,175.68	12,518.86
	E) Finance Costs	25.87	27.43	20.98	101.29
	F) Deprecation and Amortisation Expense	388.43	368.28	347.72	1,449.96
	G) Other Expenses	3,139.65	4,089.40	2,912.11	13,699.78
	Total Expenses (2)	**15,399.29**	**16,637.94**	**13,394.92**	**58,885.89**
3	**Profit / (Loss) Before Exceptional Items & Tax (1-2)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
4	Exceptional Items	Nil	Nil	Nil	Nil
5	**Profit / (Loss) after Exceptional items but Before Tax (3-4)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
6	Tax Expense				
	A) Current Tax	535.30	861.90	412.30	2,737.10
	B) Deferred Tax	596.63	(360.98)	359.10	(3.09)
	C) Short / (Excess) Tax Provision	Nil	5.88	Nil	39.11
7	**Net Profit / (Loss) For The Period (5-6)**	**3,623.45**	**1,163.46**	**2,767.52**	**8,789.38**
8	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	41.88	160.63	2.29	167.50
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
9	**Total Comprehensive Income**	**3,665.33**	**1,324.09**	**2,769.81**	**8,956.88**
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity				73,760.23
12	**Earnings Per Share (of Rs. 10/- Each) (Not Annualised)**				
	(a) Basic	18.09	5.81	13.82	43.88
	(b) Diluted	18.09	5.81	13.82	43.88

NOTES:

1. The above unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 13, 2026. The auditor have carried out an limited review of the said financial results.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. The figures for the quarter ended March 31, 2026 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
4. The Company has a single business segment namely 'Pharmaceutical Business'.
5. The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited

LINCOLN PHARMACEUTICALS LTD.

MGPatel

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: August 13, 2026

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.
CIN: L24230GJ1995PLC024288, **Ph. No.:** +91-79-4107-8000,
Website: www.lincolnpharma.com, **E-Mail:** investor@lincolnpharma.com

Statement of Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2026.

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30/06/2026 (Un-Audited)	31/03/2026 Refer No. 3	30/06/2025 (Un-Audited)	31/03/2026 (Audited)
1	**Income**				
	A) Revenue From Operations	17,728.21	18,727.73	15,406.67	67,102.99
	B) Other Income	2,426.46	(419.53)	1,527.17	3,345.40
	Total Income (1)	**20,154.67**	**18,308.20**	**16,933.84**	**70,448.39**
2	**Expenses**				
	A) Cost of Material Consumed	5,857.86	7,372.58	6,096.93	23,957.41
	B) Purchase of Stock-In-Trade	2,093.36	1,644.69	1,583.06	7,902.55
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	563.09	(110.23)	(741.56)	(743.96)
	D) Employee Benefits Expenses	3,331.03	3,245.79	3,175.68	12,518.86
	E) Finance Costs	25.87	27.44	20.98	101.30
	F) Deprecation and Amortisation Expense	388.43	368.28	347.72	1,449.96
	G) Other Expenses	3,139.65	4,089.39	2,912.11	13,699.77
	Total Expenses (2)	**15,399.29**	**16,637.94**	**13,394.92**	**58,885.89**
3	**Profit / (Loss) Before Exceptional Items & Tax (1-2)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
4	Exceptional Items	Nil	Nil	Nil	Nil
5	**Profit / (Loss) after Exceptional items but Before Tax (3-4)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
6	Tax Expense				
	A) Current Tax	535.30	861.90	412.30	2,737.10
	B) Deferred Tax	596.63	(360.98)	359.10	(3.09)
	C) Short / (Excess) Tax Provision	Nil	5.88	Nil	39.11
7	**Net Profit / (Loss) For The Period (5-6)**	**3,623.45**	**1,163.46**	**2,767.52**	**8,789.38**
8	Attributable to Non-Controlling Interest	Nil	Nil	Nil	Nil
	Atributable to Owners of the Company	**3,623.45**	**1,163.46**	**2,767.52**	**8,789.38**
9	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	41.88	160.63	2.29	167.50
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
10	**Total Comprehensive Income**	**3,665.33**	**1,324.09**	**2,769.81**	**8,956.88**
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
12	Other Equity				73,760.23
13	**Earnings Per Share (of Rs. 10/- Each) (Not Annualised)**				
	(a) Basic	18.09	5.81	13.82	43.88
	(b) Diluted	18.09	5.81	13.82	43.88

NOTES:

1. The above unaudited consolidated financial results of the Company for the quarter ended June 30, 2026 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 13, 2026. The auditor have carried out an limited review of the said financial results.
2. This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. The figures for the quarter ended March 31, 2026 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
4. The Company has a single business segment namely 'Pharmaceutical Business'.
5. The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
6. Consolidated Results includes results of its subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited

LINCOLN PHARMACEUTICALS LTD.

MgPatel

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: August 13, 2026